Related Experiment Video
Updated: Jan 11, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
BIGH3 as a potential biomarker for fibrosis in metabolic dysfunction-associated steatotic liver disease: insights
Zhenjie Zhuang1, Fen Zhuge1, Yinlan Liu1
1Center for Translational Medicine, the Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang Province, 310000, China.
Background:
Liver fibrosis is the strongest predictor of long-term clinical outcomes in patients with metabolic dysfunction-associated steatotic liver disease MASLD. Non-invasive methods for identifying these patients are urgently needed. We aimed to investigate the link between the transforming growth factor-β induced protein Ig-H3 (BIGH3) and fibrosis in both diet-induced mouse model and patients with MASLD, and explore its potential use as a biomarker for MASLD related fibrosis.
Methods:
Hepatic gene expression and serum BIGH3 levels were studied in two diet -induced MASLD models. Forty patients with biopsy-proven MASLD were recruited. Serum BIGH3 levels were measured by enzyme-linked immunosorbent assays. The difference between groups with or without fibrosis was analyzed using the Mann-Whitney U test. BIGH3 levels across different fibrosis stages were analyzed using Spearman correlation, Kruskal-Wallis test, and Dunn's post-hoc test. The receiver operating characteristic (ROC) curve was used to explore its value in the diagnosis of MASLD related fibrosis.
Results:
Bigh3 was identified as a fibrosis-related gene in the liver. Serum BIGH3 levels were significantly higher in the mouse model of fibrosis than in controls (P < 0.01). Additionally, serum BIGH3 levels were significantly elevated in MASLD patients with fibrosis compared to those without fibrosis (P < 0.01), and showed a stepwise increase corresponding to the degree of fibrosis (ρ = 0.55, P < 0.01). The areas under the receiver operating characteristic curve to discriminate significant fibrosis were 0.790 (P < 0.01).
Conclusion:
BIGH3 is a potential non-invasive biomarker of MASLD related fibrosis. It may be beneficial for diagnosing significant fibrosis in MASLD patients.
